(Press-News.org) The drug dasabuvir (trade name Exviera) has been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy.
According to the findings, there are indications of an added benefit in patients who have not yet developed cirrhosis of the liver and who are infected with the hepatitis C virus (HCV) genotype 1a. In case of genotype 1b, this only applies to treatment-naive, but not to treatment-experienced patients. The extent of added benefit is non-quantifiable, however. No added benefit can be derived from the dossier for seven other Patient groups.
Differentiated approvals result in a large number of patient groups
Dasabuvir is only approved in combination with other drugs (ombitasvir/paritaprevir/ritonavir and/or ribavirin). The Summaries of Product Characteristics specify partly different treatment regimens both for these drugs or drug combinations and for the respective comparator therapies. This results in as many as ten patient groups for this benefit assessment, which mainly differ in type of virus, pretreatment and stage of disease.
Two direct comparative studies
All ten groups were reflected in the dossier compiled by the drug manufacturer, but the data were informative for only three of these groups. The benefit assessment was based on two randomized controlled approval studies (MALACHITE I and II), in which dasabuvir in combination with ombitasvir/paritaprevir/ritonavir and/or ribavirin was directly compared with triple therapy consisting of telaprevir, pegylated interferon and ribavirin.
In compliance with the approval, the new fixed-dose combination was administered in the intervention arm for a period of 12 weeks, whereas treatment in the comparator arm could last up to 48 weeks, depending on response to the treatment.
Patients in the intervention arm were free of the virus more frequently
These two studies provided conclusive results for patients who have not yet developed cirrhosis of the liver and who are infected with a virus of genotype 1a or 1b. In genotype 1a, this applies both to treatment-naive patients and to patients who had relapsed after initially successful treatment. In genotype 1b, appropriate data were available only for treatment-naive patients.
In these three patient groups, the data showed a statistically significant difference in sustained virologic response (SVR) in favour of the new fixed-dose combination. IQWiG derived an indication of an added benefit from this. Its extent is non-quantifiable, however. It remained unclear in how many patients in whom the virus is no longer detectable, late complications, and liver cancer in particular, can actually be prevented.
Quality of life: advantage in treatment-naive patients
For the first time in the assessment of a hepatitis C drug, the manufacturer dossier contained evaluable data on health-related quality of life, which is of particular importance regarding interferon, which is considered to be very burdensome. These data on quality of life showed an advantage of dasabuvir at least for the duration of treatment. This applies to certain treatment-naive genotype 1a or 1b patients, but not to treatment-experienced patients (genotype 1a). It depends on the severity of the disease whether they have an advantage and how big this advantage is.
IQWiG derived a hint of an added benefit with differing extent from these data.
Data on side effects partly not conclusively interpretable
The important differences in treatment duration between intervention and control arm, which could be up to 36 weeks, partly made it impossible to interpret differences in side effects. Since the observation periods also differed, the results were probably biased.
Regarding the robustness of the data, however, there were exceptions in certain patient groups or aspects of side effects (serious adverse events and treatment discontinuation). In each case, the results were in favour of the new fixed-dose combination.
IQWiG therefore sees a hint or an indication of lesser harm in treatment-naive genotype 1b patients and an indication of lesser harm in treatment-experienced genotype 1a patients for individual aspects of side effects. Overall, greater or lesser harm is not proven.
Robust data were lacking for further patient groups
The dossier contained no suitable data for the remaining seven patient groups (genotype 1). Since direct comparative studies were lacking, the manufacturer referred to results on dasabuvir, in which the drug was not tested against the appropriate comparator therapy, however. No systematic comparison with data on the appropriate comparator therapy was conducted. Since there was also no systematic search for studies on the comparator therapies, it can be assumed that the data were incomplete.
Overall, an indication of a non-quantifiable added benefit can be derived from the dossier for three patient groups: patients without cirrhosis of the liver infected with genotype 1a (treatment-naive and treatment-experienced) and with genotype 1b who have not been pretreated.
G-BA decides on the extent of added benefit
This dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
INFORMATION:
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language information.
More English-language information will be available soon (Sections 2.1 to 2.7 of the dossier assessment as well as subsequently published health information on » http://www.informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.
Radio systems, such as mobile phones and wireless internet connections, have become an integral part of modern life. However, today's devices use twice as much of the radio spectrum as is necessary. New technology is being developed that could fundamentally change radio design and could increase data rates and network capacity, reduce power consumption, create cheaper devices and enable global roaming.
A pioneering team of researchers from the University of Bristol's Communication Systems and Networks research group, have developed a new technique that can estimate ...
Oral care products containing a natural chemical that stops bacteria harming teeth could help prevent decay, a study suggests.
The plant natural product acts against harmful mouth bacteria and could improve oral health by helping to prevent the build-up of plaque, researchers say.
The compound - known as trans-chalcone - is related to chemicals found in liquorice root. The study shows that it blocks the action of a key enzyme that allows the bacteria to thrive in oral cavities.
The bacteria - Streptococcus mutans - metabolise sugars from food and drink, which produces ...
Some mountain gorilla females linger into adulthood in the group into which they were born. In the process, they also remain in the company of their father, who is often their group's dominant male. To curb inbreeding, though, they appear to tactically avoid mating with their fathers. This strategy works so well that the chances of alpha gorilla males siring the offspring of their own daughters are effectively zero, according to Linda Vigilant of the Max Planck Institute for Anthropology in Germany. The findings are published in Springer's journal Behavioral Ecology and ...
CAMBRIDGE, Mass--Researchers have found a way to couple the properties of different two-dimensional materials to provide an exceptional degree of control over light waves. They say this has the potential to lead to new kinds of light detection, thermal-management systems, and high-resolution imaging devices.
The new findings -- using a layer of one-atom-thick graphene deposited on top of a similar 2-D layer of a material called hexagonal boron nitride (hBN) -- are published in the journal Nano Letters. The work is co-authored by MIT associate professor of mechanical engineering ...
The rapid evolution of gadgets has brought us an impressive array of "smart" products from phones to tablets, and now watches and glasses. But they still haven't broken free from their rigid form. Now scientists are reporting in the journal ACS Applied Materials & Interfaces a new step toward bendable electronics. They have developed the first light-emitting, transparent and flexible paper out of environmentally friendly materials via a simple, suction-filtration method.
Technology experts have long predicted the coming age of flexible electronics, and researchers have ...
Scientists from General Atomics and the U.S. Department of Energy's (DOE) Princeton Plasma Physics Laboratory (PPPL) have discovered a phenomenon that helps them to improve fusion plasmas, a finding that may quicken the development of fusion energy. Together with a team of researchers from across the United States, the scientists found that when they injected tiny grains of lithium into a plasma undergoing a particular kind of turbulence then, under the right conditions, the temperature and pressure rose dramatically. High heat and pressure are crucial to fusion, a process ...
(PARIS, FRANCE) - Clearing blood clots from arteries during treatment for an acute myocardial infarction was a relatively common practice until a recent, large-scale study showed that the technique, known as thrombectomy, might actually increase the risk of stroke. Now, new insights from the TOTAL trial, presented here at EuroPCR 2015, indicate that the risk of stroke with thrombectomy during angioplasty, compared to angioplasty alone is evident very early following the procedure.
Dr. Sanjit Jolly, the study's lead author and an interventional cardiologist and Associate ...
This beautiful planetary nebula is named after a dreadful creature from Greek mythology -- the Gorgon Medusa. It is also known as Sharpless 2-274 and is located in the constellation of [Gemini] (The Twins). The Medusa Nebula spans approximately four light-years and lies at a distance of about 1500 light-years. Despite its size it is extremely dim and hard to observe.
Medusa was a hideous creature with snakes in place of hair. These snakes are represented by the serpentine filaments of glowing gas in this nebula. The red glow from hydrogen and the fainter green emission ...
Noise from pile driving during offshore wind turbine construction could be damaging the hearing of harbour seals around the UK, according to ecologists who attached GPS data loggers to 24 harbor seals while offshore wind turbines were being installed in 2012. Data on the seals' locations and their diving behaviour was combined with information from the wind farm developers on when pile driving was taking place. Models revealed that half of the tagged seals were exposed to noise levels that exceeded hearing damage thresholds.
There are currently 1,184 offshore wind turbines ...
The harlequin ladybird, officially known as Harmonia axyridis, was widely introduced across continental Europe as a way to limit the population of small sap-sucking insects called aphids. While it was never intentionally introduced into Britain, H. axyridis was discovered there in 2003, and people across the region have been tracking its spread since 2005.
A new review in The Royal Entomological Society's journal Ecological Entomology notes that tens of thousands of people have provided records of H. axyridis and other species of ladybirds, creating an invaluable dataset ...
